In conclusion, by using non-invasive whole blood profiling, we identified and validated POU2AF1, TCL1A, and BLK as three predictive biomarkers of BOS, more than 6 months before diagnosis. Here, TCL1A is linked to Buschke-Ollendorff syndrome.